Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Modena – page 6

387 clinical trials in Modena, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Modena at a glance
387
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

387 trials in Modena

Open in trial search

Non-small cell lung cancer+1

Recruiting

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Prostate cancer

Recruiting

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:DB-1303
  • Sponsor:BioNTech SE

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Rectal cancer

Recruiting

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Medizinische Hochschule Hannover

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Atrial fibrillation

Recruiting

Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AP31969 sulfate
  • Sponsor:Acesion Pharma ApS

Colorectal cancer

Recruiting

Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

Immune thrombocytopenia

Recruiting

Study of efgartigimod given by IV infusion in adolescents aged 12-17 years with chronic immune thrombocytopenia

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Bacteraemia

Recruiting

Comparing piperacillin-tazobactam and meropenem for treating bloodstream infections caused by cephalosporin-resistant bacteria in adult patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Meropenem Anhydrous
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Modena

What the registry says about research in the country

01 Respiratory Medicine

Innovative clinical trials exploring treatments for pulmonary fibrosis and severe asthma, evaluating novel therapies aimed at improving lung function and patient outcomes.

  • Idiopathic Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis
  • High-Risk Asthma

Research focuses on evaluating forced vital capacity changes and reducing asthma exacerbations.

02 Autoimmune Conditions

Groundbreaking studies examining treatments for systemic sclerosis and related autoimmune disorders, with emphasis on innovative biological therapies.

  • Diffuse Cutaneous Systemic Sclerosis
  • Systemic Autoimmune Rheumatic Diseases
  • Interstitial Lung Diseases

Studies aim to improve skin sclerosis and manage associated complications.

03 Oncology Research

Advanced trials investigating treatments for various cancers, including gastric cancer and hematological malignancies.

  • HER2-positive Gastric Cancer
  • Follicular Lymphoma
  • Metastatic Renal Cell Carcinoma

Focus on immunotherapy combinations and targeted treatments for better patient outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.